Medindia

X

Medarex Announces Presentations on UltiMAb(R) Antibodies at 71st Annual Meeting of the American College of Rheumatology

Friday, November 9, 2007 General News J E 4
Advertisement
PRINCETON, N.J., Nov. 8 Medarex, Inc.(Nasdaq: MEDX) announced today that at least five antibodies generated fromMedarex's UltiMAb(R) technology in which Medarex wholly owns or has aneconomic interest through co-promote/profit sharing rights, royalties and/orequity ownership, are expected to be the subject of oral or posterpresentations at the 71st Annual Meeting of the American College ofRheumatology (ACR), being held November 6-11, 2007 in Boston.

Golimumab (CNTO 148) and ustekinumab (CNTO 1275) Phase III or Phase IIclinical data for inflammatory diseases in development by Medarex's licensingpartner, Centocor, Inc.

On November 1, 2007, Johnson & Johnson announced that it will sponsor ananalyst meeting and webcast on Thursday, November 8, 2007, from 5:00-6:00 P.M.Eastern Time to discuss late-stage compounds, including golimumab andustekinumab.

Ofatumumab (HuMax-CD20) Phase II clinical data for rheumatoid arthritis indevelopment by Medarex's licensing partner, Genmab A/S

MEDI-545 Phase I clinical data for systemic lupus erythematosus indevelopment by Medarex's partner, MedImmune, Inc.

Abstracts and information about the ACR and its Annual Meeting may befound at www.rheumatology.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery,development and potential commercialization of fully human antibody-basedtherapeutics to treat life-threatening and debilitating diseases, includingcancer, inflammation, autoimmune disorders and infectious diseases. Medarexapplies its UltiMAb(R) technology and product development and clinicalmanufacturing experience to generate, support and potentially commercialize abroad range of fully human antibody product candidates for itself and itspartners. More than 30 of these therapeutic product candidates derived fromMedarex technology are in human clinical testing or have had INDs submittedfor such trials, with seven of the most advanced product candidates currentlyin Phase III clinical trials. Medarex is committed to building value bydeveloping a diverse pipeline of antibody products to address the world'sunmet healthcare needs. For more information about Medarex, visit its websiteat www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks ofMedarex, Inc. All rights are reserved.-- "Golimumab, a new, human TNF-alpha antibody administered as a monthly subcutaneous injection in ankylosing spondylitis (AS): 24-week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study" (Presentation #L10, Spondylarthropathies and Psoriatic Arthritis Session) - Poster presentation scheduled for Thursday, November 8, 2007 at 8:00 A.M. -- "Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFa" (Presentation #274, RA Treatment: Small Molecules Sessions) - Poster presentation scheduled for Thursday, November 8, 2007 at 8:00 A.M. -- "Phase II, randomized, placebo-controlled study of CNTO 1275, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis" (Presentation #L16, Spondylarthropathies and Psoriatic Arthritis Session) - Oral presentation scheduled for Saturday, November 10, 2007 at 3:15 P.M. -- "Golimumab, a new human TNF-alpha antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study" (Presentation #L14, Spondylarthropathies and Psoriatic Arthritis Session) - Oral presentation scheduled for Saturday, November 10, 2007 at 2:45 P.M.

SOURCE Medarex, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Repligen Reports Positive Phase 2a Clinical Trial ...
S
Neurochem announces important initiatives to provi...